Acute Myeloid Leukaemia Clinical Trials

56 clinical trials for Acute Myeloid Leukaemia across international registries, including 14 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML — RECRUITING · PHASE2
• RVU120 Rollover Study — RECRUITING · PHASE2
• A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies — RECRUITING
• Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression — RECRUITING · PHASE1
• Leukemia Adapted Protocol — RECRUITING
• A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax — RECRUITING · PHASE1
• Maintenance Venetoclax in AML Fit Patients — RECRUITING · NA
• Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia — RECRUITING · NA
• Clinical Study of U32 in Patients With Acute Myeloid Leukemia — RECRUITING · PHASE1
• Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation — RECRUITING · PHASE2
• Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation — RECRUITING · PHASE2
• Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia — RECRUITING · NA
• MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) — RECRUITING · PHASE3
• Randomized phase III study comparing the OSHO arm to the standard therapy arm of Geman AML Intergroup. Randomized comparison of Cytarabine and Mitoxantrone versus Fludarabine, Cytarabine, Mitoxantron and G-CSF treatment in patients not in remission after the first induction chemotherapy. Randomized comparison between one or two chemotherapy consolidation courses before autologous or allogeneic human stem cell transplantation in adult patients with AML under the age of 60 years. — RECRUITING
• A PHASE II TRIAL OF CLOFARABINE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA FOR WHOM INTENSIVE CHEMOTHERAPY IS NOT CONSIDERED SUITABLE — COMPLETED · PHASE2
• A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional Chemotherapy — TERMINATED · PHASE2
• Phase 1 Open-label Study of AMX-883 Alone in Participants With AML and High-risk MDS and in Combination in Participants With AML — NOT_YET_RECRUITING · PHASE1
• International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy — NOT_YET_RECRUITING · PHASE2
• Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics — COMPLETED · PHASE1
• A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT — ACTIVE_NOT_RECRUITING · PHASE2
• VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided phase 2 study — TERMINATED · PHASE2
• Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker — NOT_YET_RECRUITING · PHASE2
• Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome — COMPLETED
• HOVON 171 AML: A single arm phase II trial to assess cobicistat boosted venetoclax in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (AML) who are not considered candidates for intensive treatment regimens — TERMINATED · PHASE2
• Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study — NOT_YET_RECRUITING · PHASE2
• Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• AI-Assisted Acute Myeloid Leukemia Evaluation With the Leukemia End-to-End Analysis Platform (LEAP) Versus Clinician-Only Assessment — COMPLETED · NA
• Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) — COMPLETED · PHASE1
• A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T) — OTHER · PHASE3
• Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care — NOT_YET_RECRUITING · NA
• GITMO AML/MDS-Relapse Registry Study — COMPLETED
• NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial — NOT_YET_RECRUITING · PHASE2
• Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia — COMPLETED · PHASE1
• Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers — COMPLETED · PHASE2
• Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia. — COMPLETED · PHASE1
• Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a — COMPLETED · PHASE3
• Panobinostat Maintenance After HSCT fo High-risk AML and MDS — TERMINATED · PHASE3
• Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome — COMPLETED · PHASE1
• Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. — TERMINATED · PHASE1
• Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia — WITHDRAWN · PHASE1
• Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations — OTHER · PHASE2
• Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome — COMPLETED · PHASE1
• WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study — COMPLETED · PHASE1
• A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients — COMPLETED · PHASE1
• Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) — COMPLETED · PHASE1
• Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia — COMPLETED
• A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia — COMPLETED · PHASE2
• Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation — OTHER · PHASE1

Refine this search